180 related articles for article (PubMed ID: 29604495)
1. Is alpha-fetoprotein decline a prognostic factor of childhood non-seminomatous germ cell tumours? Results of the French TGM95 study.
Fresneau B; Orbach D; Faure-Conter C; Sudour-Bonnange H; Vérité C; Gandemer V; Pasquet M; Fasola S; Rome A; Raimbault S; Martelli H; Frappaz D; Le Teuff G; Patte C
Eur J Cancer; 2018 May; 95():11-19. PubMed ID: 29604495
[TBL] [Abstract][Full Text] [Related]
2. Childhood ovarian nonseminomatous germ cell tumors: A highly curable disease with few long-term treatment-related toxicities-Results of the French TGM95 study.
Pavone R; Pacquement H; Pasquet M; Sudour-Bonnange H; Hameury F; Sarnacki S; Chastagner P; Faure-Conter C; Poirée M; Taque S; Patte C; Fresneau B
Int J Cancer; 2021 Nov; 149(9):1705-1712. PubMed ID: 34146403
[TBL] [Abstract][Full Text] [Related]
3. Extracranial germ cell tumours in children and adolescents: Results from the French TGM13 protocol.
Faure-Conter C; Orbach D; Sudour-Bonnange H; Verité C; Mansuy L; Rome A; Dumesnil C; Thebaud E; Renard M; Hameury F; Flechon A; Blanc E; Dijoud F; Fresneau B; Chabaud S
Pediatr Blood Cancer; 2023 Mar; 70(3):e30117. PubMed ID: 36451268
[TBL] [Abstract][Full Text] [Related]
4. Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation.
Raggi D; Mariani L; Giannatempo P; Lo Vullo S; Giardiello D; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Calareso G; Magni M; Di Nicola M; Verzoni E; Grassi P; Procopio G; De Braud F; Pizzocaro G; Salvioni R; Necchi A
Urol Oncol; 2015 Jul; 33(7):332.e19-24. PubMed ID: 25985712
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of tumor size, metastases, extension into bone, and increased tumor marker in children with malignant sacrococcygeal germ cell tumors: a prospective evaluation of 71 patients treated in the German cooperative protocols Maligne Keimzelltumoren (MAKEI) 83/86 and MAKEI 89.
Calaminus G; Schneider DT; Bökkerink JP; Gadner H; Harms D; Willers R; Göbel U
J Clin Oncol; 2003 Mar; 21(5):781-6. PubMed ID: 12610174
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
You B; Fronton L; Boyle H; Droz JP; Girard P; Tranchand B; Ribba B; Tod M; Chabaud S; Coquelin H; Fléchon A
Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic accuracy of preoperative alpha-fetoprotein as an ovarian tumor marker in children and adolescents: not as good as we thought?
Loh AH; Gee KW; Chua JH
Pediatr Surg Int; 2013 Jul; 29(7):709-13. PubMed ID: 23653236
[TBL] [Abstract][Full Text] [Related]
8. [The prognostic significance of serum alpha 1-fetoprotein in children and adolescents with malignant extracranial non-testicular germ cell tumors].
Calaminus G; Vesterling-Hörner D; Bökkerink JP; Gadner H; Günther G; Haas HJ; Jürgens H; Teske C; Göbel U
Klin Padiatr; 1991; 203(4):246-50. PubMed ID: 1719268
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in children with localized malignant nonseminomatous germ cell tumors.
Baranzelli MC; Kramar A; Bouffet E; Quintana E; Rubie H; Edan C; Patte C
J Clin Oncol; 1999 Apr; 17(4):1212. PubMed ID: 10561181
[TBL] [Abstract][Full Text] [Related]
10. Actual half-life of alpha-fetoprotein as a prognostic tool in pediatric malignant tumors.
Han SJ; Yoo S; Choi SH; Hwang EH
Pediatr Surg Int; 1997; 12(8):599-602. PubMed ID: 9354734
[TBL] [Abstract][Full Text] [Related]
11. Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease.
Gerl A; Clemm C; Lamerz R; Mann K; Wilmanns W
Eur J Cancer; 1993; 29A(7):961-5. PubMed ID: 7684597
[TBL] [Abstract][Full Text] [Related]
12. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
[TBL] [Abstract][Full Text] [Related]
13. α-Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium.
O'Neill AF; Xia C; Krailo MD; Shaikh F; Pashankar FD; Billmire DF; Olson TA; Amatruda JF; Villaluna D; Huang L; Malogolowkin M; Rodriguez-Galindo C; Frazier AL
Cancer; 2019 Oct; 125(20):3649-3656. PubMed ID: 31355926
[TBL] [Abstract][Full Text] [Related]
14. Lectin-reactive alpha-fetoprotein (AFP-L3%) curability and prediction of clinical course after treatment of non-seminomatous germ cell tumors.
Kamoto T; Satomura S; Yoshiki T; Okada Y; Henmi F; Nishiyama H; Kobayashi T; Terai A; Habuchi T; Ogawa O
Jpn J Clin Oncol; 2002 Nov; 32(11):472-6. PubMed ID: 12499420
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of tumor marker decline as an independent prognostic factor in patients with relapsed metastatic germ-cell tumors.
Mego M; Rejlekova K; Reckova M; Sycova-Mila Z; Obertova J; Rajec J; Mardiak J
Neoplasma; 2009; 56(5):398-403. PubMed ID: 19580341
[TBL] [Abstract][Full Text] [Related]
16. Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.
Massard C; Kramar A; Beyer J; Hartmann JT; Lorch A; Pico JL; Rosti G; Droz JP; Fizazi K
Ann Oncol; 2013 Feb; 24(2):322-328. PubMed ID: 23104726
[TBL] [Abstract][Full Text] [Related]
17. Malignant extra-cranial germ cell tumors in children and adolescents. Results following the guidelines of SFOP/SFCE 95 Protocol.
Zubizarreta P; Rossa A; Bailez M; Gil S; Rose A; Cacciavillano W
Medicina (B Aires); 2016; 76(5):265-272. PubMed ID: 27723613
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors.
de la Motte Rouge T; Pautier P; Genestie C; Rey A; Gouy S; Leary A; Haie-Meder C; Kerbrat P; Culine S; Fizazi K; Lhommé C
Gynecol Oncol; 2016 Sep; 142(3):452-7. PubMed ID: 27401840
[TBL] [Abstract][Full Text] [Related]
19. Management of germ cell tumors in children: approaches to cure.
Göbel U; Calaminus G; Schneider DT; Schmidt P; Haas RJ;
Onkologie; 2002 Feb; 25(1):14-22. PubMed ID: 11893878
[TBL] [Abstract][Full Text] [Related]
20. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy.
Murphy BA; Motzer RJ; Mazumdar M; Vlamis V; Nisselbaum J; Bajorin D; Bosl GJ
Cancer; 1994 May; 73(10):2520-6. PubMed ID: 7513603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
